Karyopharm Therapeutics Inc

KPTI13 Dec 2024
Healthcare
$0.71
0.00 (-0.12%)
Lowest Today
$0.71
Highest Today
$0.73
Today’s Open
$0.71
Prev. Close
$0.72
52 Week High
$1.95
52 Week Low
$0.66
To Invest in Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc

Healthcare
KPTI13 Dec 2024
0.00 (-0.12%)
1M
3M
6M
1Y
5Y
Low
$0.71
Day’s Range
High
$0.73
0.71
52 Week Low
$0.66
52-Week Range
52 Week High
$1.95
0.66
1 Day
-
1 Week
-3.89%
1 month return
-14.35%
3 month return
-4.4%
6 month return
-27.95%
1 Year return
-3.72%
3 Years return
-87.83%
5 Years return
-95.61%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
6.11
Eversept Partners, LLC
4.43
Palo Alto Investors, LLC
4.07
Adage Capital Partners Gp LLC
3.45
BlackRock Inc
3.33
Vanguard Total Stock Mkt Idx Inv
2.73
Citadel Advisors Llc
2.48

Market Status

Fundamentals
Market Cap
91.35 mln
PB Ratio
12.05
PE Ratio
0
Enterprise Value
152.21 mln
Total Assets
240.44 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Organisation
Karyopharm Therapeutics Inc
Employees
325
Industry
Biotechnology
CEO
Mr. Richard A. Paulson M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities